Journal of the American Academy of Dermatology
Volume 60, Issue 1 , Pages 154-157 , January 2009

Folliculitis-perifolliculitis related to erlotinib therapy spares previously irradiated skin

  • Jayati Acharya, MRCP

      Affiliations

    • Department of Clinical Oncology, St James's Institute of Oncology, Leeds, United Kingdom
    • Corresponding Author InformationCorrespondence to: Jayati Acharya, MRCP, Department of Clinical Oncology, St James's Institute of Oncology, Beckett Street, Leeds, West Yorkshire, United Kingdom LS9 7TF.
    • ,
  • Calum Lyon, MA, FRCP

      Affiliations

    • Department of Dermatology, York District Hospital, York, United Kingdom
    • ,
  • David M. Bottomley, MRCP, FRCR

      Affiliations

    • Department of Clinical Oncology, St James's Institute of Oncology, Leeds, United Kingdom

References 

  1. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004;22:133–142
  2. King LE, Gates RE, Stoscheck CM, Nanney LB. The EGF/TGF alpha receptor in skin. J Invest Dermatol. 1990;94(6 suppl):164S–170S
  3. Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol. 1997;8:1197–1206
  4. Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al. Determinants of tumor response and survival with erlotinib in patients with non–small-cell lung cancer. J Clin Oncol. 2004;22:3238–3247
  5. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22:77–85
  6. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol. 2002;20:2240–2250
  7. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol. 2002;20:3815–3825
  8. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001;19:3267–3279
  9. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16:1425–1433
  10. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6:491–500
  11. Busam KJ, Capodieci P, Motzer R, Keihn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol. 2001;144:1169–1176
  12. Nasca MR, Micali G, Ferrau F. Steroid acne sparing an area of previous irradiation. Acta Derm Venereol. 1995;75:495
  13. Sanz A, del Valle ML. A man whose scapula was spared a drug-associated rash. CMAJ. 2005;172:745
  14. Bernhard JD, Haynes HA. Nonrashes. Part I: the Koebner nonreaction. Cutis. 1982;29:158–164
  15. Archambeau JO, Pezner R, Wasserman T. Pathophysiology of irradiated skin and breast. Int J Radiat Oncol Biol Phys. 1995;31:1171–1185
  16. Sivan V, Vozenin-Brotons MC, Tricaud Y, Lefaix JL, Cosset JM, Dubray B, et al. Altered proliferation and differentiation of human epidermis in cases of skin fibrosis after radiotherapy. Int J Radiat Oncol Biol Phys. 2002;53:385–393
  17. Bossi P, Liberatoscioli C, Bergamini C, Locati LD, Fava S, Rinaldi G, et al. Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients. Ann Oncol. 2007;18:601–602
  18. Dutreix J. Human skin: early and late reactions in relation to dose and its time distribution. Br J Radiol Suppl. 1986;19:22–28
  19. Turesson I, Nyman J, Holmberg E, Odén A. Prognostic factors for acute and late skin reactions in radiotherapy patients. Int J Radiat Oncol Biol Phys. 1996;36:1065–1075
  20. Bentzen SM, Overgaard J. Patient-to-patient variability in the expression of radiation-induced normal tissue injury. Semin Radiat Oncol. 1994;4:68–80

 Funding sources: None.

 Conflicts of interest: None declared.

 Reprints not available from authors.

PII: S0190-9622(08)01015-3

doi: 10.1016/j.jaad.2008.07.057

Journal of the American Academy of Dermatology
Volume 60, Issue 1 , Pages 154-157 , January 2009

Article Tools

* Image Usage & Resolution